Scarica l'app Stockscreener
0.2983
3.15%
-0.0097
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
Two Sigma Investments LP Boosts Stock Position in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
Cognition Therapeutics (CGTX) Secures Donation to Support Dement - GuruFocus
Cognition Therapeutics Launches Expanded Access Program for Zervimesine - TipRanks
Cognition Therapeutics Announces Expanded Access Program for Dementia with Lewy Bodies, Led by Dr. James Galvin - Nasdaq
Philanthropic Donor Funds Cognition Therapeutics’ Expanded - GlobeNewswire
Major Breakthrough: Donor Funds New Treatment Access for Lewy Body Dementia Patients - Stock Titan
B. Riley Expects Reduced Earnings for Cognition Therapeutics - Defense World
HC Wainwright Issues Positive Forecast for CGTX Earnings - Defense World
Alzheimer's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Cognition Therapeutics Releases New Episode of - GlobeNewswire
Lewy Body Dementia Caregivers Share Powerful Stories Alongside Leading Neurologists in New Medical Podcast - Stock Titan
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies - GlobeNewswire
CGTX: HC Wainwright & Co. Lowers Price Target While Maintaining Buy Rating | CGTX Stock News - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Exp - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Expected Equity Dilution | CGTX Stock News - GuruFocus
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Chardan Capital Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World
Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down - Nasdaq
Cognition announces outcomes from trial of zervimesine for geographic atrophy - Yahoo Finance
Cognition Therapeutics Inc (NASDAQ: CGTX) Stock Price Forecast: $100 - Stocksregister
Cognition Therapeutics Reports Promising Preclinical Data for Zervimesine in Protecting RPE Cells from Dry AMD at ARVO 2025 - Nasdaq
Cognition Therapeutics Presented Data at Association for - GlobeNewswire
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - Stock Titan
zervimesine shows promise in dry AMD trial - Investing.com
Cognition Therapeutics Reports Q1 2025 Financials and Progress - TipRanks
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics - Ophthalmology Times
zervimesine shows promise in dry AMD trial By Investing.com - Investing.com South Africa
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial - HCPLive
Cognition Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - Santé log
Ratio Examination: Cognition Therapeutics Inc (CGTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Cognition Therapeutics, Inc. Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - marketscreener.com
Cognition Therapeutics (CGTX) Stock Target Lowered by Chardan Ca - GuruFocus
COGNITION THERAPEUTICS INC SEC 10-Q Report - TradingView
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Advances Alzheimer’s and DLB Programs with FDA Meeting Request and Upcoming Presentations at AAIC and ARVO - Nasdaq
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides ... - Bluefield Daily Telegraph
Caregiver Distress The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters - Clinical Leader
Geode Capital Management LLC Raises Holdings in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
CES ENERGY SOLUTIONS CORP. ANNOUNCES AMENDMENT AND EXTENSION TO ITS INCREASED CREDIT FACILITY - The Globe and Mail
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com
Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com
CGTX Stock Sees Surge of Approximately 16.59% in Last Five Days - knoxdaily.com
Dry AMD Therapeutics Market Size in 7MM is expected to grow at - openPR.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
2025 Is Shaping Up To Be A Big Year For This Drug Maker Working To Cure Dementia - Benzinga
CGTX stock touches 52-week low at $0.34 amid market challenges - Investing.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of “Buy” by Analysts - Defense World
Cognition Therapeutics reports promising Alzheimer’s study results By Investing.com - Investing.com South Africa
Cognition Therapeutics reports promising Alzheimer’s study results - Investing.com
Cognition Therapeutics Presents Results at AD/PD 2025 - GlobeNewswire
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes - TradingView
Breakthrough: Cognition's Alzheimer's Drug Reduces Multiple Disease Markers in Phase 2 Trial - Stock Titan
Equities Analysts Set Expectations for CGTX FY2025 Earnings - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):